Measuring tau deposition in Alzheimer's patients using PET imaging
UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
This study is testing how much tau protein is in the brains of people with Alzheimer's to see how it relates to their health and background.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Birmingham, Alabama) |
| Trial ID | NCT03809351 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the concentration and distribution of tau protein in the brains of participants with Alzheimer's disease using the PET tracer AV-1451. It will correlate tau levels with demographic, clinical, genetic, and biospecimen data from the ongoing UAB-ADC cohort. Additionally, the study will explore the interactions between race, vascular risk factors, and cognitive status in relation to tau levels. Participants will also be involved in a related amyloid-PET study to compare findings on amyloid and tau deposition.
Who should consider this trial
Good fit: Ideal candidates include individuals enrolled in the UAB-ADC study who are also participating in the amyloid-PET substudy.
Not a fit: Patients with severe dementia or those unable to undergo MRI or PET imaging will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of tau pathology in Alzheimer's disease and improve diagnostic and therapeutic strategies.
How similar studies have performed: Other studies using PET imaging for tau deposition have shown promising results, indicating that this approach is supported by prior research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Enrollment in the UAB-ADC study under a separate IRB-approved research protocol. 2. Enrollment in the UAB-ADC amyloid-PET substudy under a separate IRB-approved research protocol. The amyloid-PET study does not have to have been completed prior to enrollment and participation in this tau-PET study. 3. Negative urine or serum hCG test within 2 days of \[F-18\]AV-1451 administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing. Exclusion Criteria: 1. Meets any exclusion criteria for the UAB-ADC study. 2. Inability or contraindication for undergoing MRI and/or PET imaging 3. Inability to participate in the imaging studies due to severity of dementia
Where this trial is running
Birmingham, Alabama
- UAB — Birmingham, Alabama, United States (Recruiting)
Study contacts
- Study coordinator: Chinara Dosse
- Email: cdosse@uabmc.edu
- Phone: (205) 934-4501
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.